可吸入乳铁蛋白-硫酸软骨素纳米复合材料用于联合递送多柔比星和鞣花酸至肺癌。
Inhalable lactoferrin-chondroitin nanocomposites for combined delivery of doxorubicin and ellagic acid to lung carcinoma.
机构信息
Cancer Nanotechnology Research Laboratory (CNRL), Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
Department of Industrial Pharmacy, Faculty of Pharmacy, Alexandria University, Alexandria 21521, Egypt.
出版信息
Nanomedicine (Lond). 2018 Aug;13(16):2015-2035. doi: 10.2217/nnm-2018-0039. Epub 2018 Sep 7.
AIM
The use of inhalable nanomedicines can overcome the Enhanced permeation and retention effect (EPR)-associated drawbacks in lung cancer therapy via systemic nanomedicines.
METHODS
We developed a lactoferrin-chondroitin sulfate nanocomplex for the co-delivery of doxorubicin and ellagic acid nanocrystals to lung cancer cells. Then, the nanocomplex was converted into inhalable nanocomposites via spray drying.
RESULTS
The resulting 192.3 nm nanocomplex exhibited a sequential faster release of ellagic acid, followed by doxorubicin. Furthermore, the nanocomplex demonstrated superior cytotoxicity and internalization into A549 lung cancer cells mediated via Tf and CD44 receptors. The inhalable nanocomposites exhibited deep lung deposition (89.58% fine particle fraction [FPF]) with powerful antitumor efficacy in lung cancer bearing mice.
CONCLUSION
Overall, inhalable lactoferrin-chondroitin sulfate nanocomposites would be a promising carrier for targeted drug delivery to lung cancer.
目的
通过全身纳米药物，吸入型纳米药物的使用可以克服增强型渗透和保留效应（EPR）相关的肺癌治疗缺陷。
方法
我们开发了一种乳铁蛋白-硫酸软骨素纳米复合物，用于同时递送达柔比星和鞣花酸纳米晶体至肺癌细胞。然后，通过喷雾干燥将纳米复合物转化为可吸入的纳米复合材料。
结果
所得 192.3nm 的纳米复合物表现出鞣花酸的顺序更快释放，随后是阿霉素。此外，纳米复合物通过 Tf 和 CD44 受体表现出对 A549 肺癌细胞的更高细胞毒性和内化作用。可吸入的纳米复合材料具有深肺部沉积（89.58%细颗粒分数[FPF]），并在携带肺癌的小鼠中具有强大的抗肿瘤功效。
结论
总体而言，可吸入的乳铁蛋白-硫酸软骨素纳米复合材料将是一种有前途的用于肺癌靶向药物递送的载体。
Zotero 插件